^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MDG1011

i
Other names: MDG1011, PRAME TCR modified CAR-T cells, MDG 1011
Associations
Trials
Company:
Medigene
Drug class:
PRAME inhibitor
Associations
Trials
over1year
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov)
P1/2, N=9, Terminated, Medigene AG | N=92 --> 9 | Trial completion date: Apr 2024 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Jun 2022; The clinical trial is terminated after the completion of phase I without moving to Phase II.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
HLA-A*02:01 • HLA-A*02 • PRAME expression • HLA-A2 positive
|
MDG1011
almost2years
FIRST-IN-HUMAN STUDY OF MDG1011, A TCR-T CELL THERAPY DIRECTED AGAINST HLA-A*02:01-RESTRICTED PRAME, FOR HIGH-RISK MYELOID AND LYMPHOID NEOPLASMS (CD-TCR-001) (EBMT 2023)
Treatment was conducted with MDG1011 after lymphodepletion with fludarabine (25 mg/m² x 3d) and cyclophosphamide (300 mg/m² x 3d) in patients with HLA-A*02:01- and PRAME-positive r/r disease...Grade 1 cytokine release syndrome (CRS) occurred in 1 patient at DL2, grade 2 CRS in 1 patient at DL3 that was manageable with tocilizumab... In heavily pre-treated patients with advanced myeloid and lymphoid neoplasms, treatment with MDG1011 was generally safe and well tolerated up to 5x106 PRAME-specific TCR-T cells/kg. Clinical observations were corroborated by persistence of MDG1011 cells in PB and reductions in PRAME mRNA levels in PB and/or BM.
P1 data
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
HLA-A*02 • PRAME expression
|
cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • MDG1011